Rationale for the use of mitoxantrone in multiple sclerosis-Reference-Cited by-同舟云学术

Rationale for the use of mitoxantrone in multiple sclerosis

Published:2004-08 Issue:1 Volume:223 Page:35-39
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Edan Gilles,Morrissey Sean,Le Page Emmanuelle

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference35 articles.

1. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation;Rosenberg;Biochemistry,1986

2. Mitoxantrone in principles of treatments in multiple sclerosis;Gilles,2000

3. Suppression of experimental allergic encephalomyelitis by mitoxantrone;Ridge;Clin. Immunol. Immunopathol.,1985

4. Selective immunomodulation by the antineoplastic agent mitoxantrone: II. Non specific adherent suppressor cells derived from mitoxantrone-treated mice;Fidler;J. Immunol.,1986

5. Selective immunomodulation by the antineoplastic agent mitoxantrone: I. Suppression of B lymphocyte function;Fidler;J. Immunol.,1986

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis;Journal of Neuroinflammation;2022-12-12

2. Progress in the Application of Drugs for the Treatment of Multiple Sclerosis;Frontiers in Pharmacology;2021-07-13

3. Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing;European Journal of Medicinal Chemistry;2018-01

4. Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models;Brain, Behavior, and Immunity;2017-05

5. Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis – study site experience based on the therapy of 104 patients;International Journal of Neuroscience;2016-12-23